Comparison of the Efficiency of ESWT and Ozone Injection in Patients With Chronic Plantar Fasciitis
Comparison of the Efficiency of Extracorporeal Shock Wave Therapy and Ultrasound-Guided Ozone Injection in Patients With Chronic Plantar Fasciitis
Extracorporeal Shock Wave Therapy (ESWT) is a conservative treatment method that has been widely used in musculoskeletal diseases in recent years. Its mechanism is to provide hyperstimulation and vascularity increase with the help of acoustic waves focused on a specific area, thus accelerating healing and reducing pain. This method, which is frequently used in plantar fasciitis, is frequently applied to patients whose symptoms persist despite first-line treatment strategies.
Ozone injections have been frequently used in musculoskeletal disorders in recent years and are mainly used in osteoarthritis, osteomyelitis, tendon, fascia and ligament injuries, vertebra and disc pathologies and neuropathic pain. Analgesic effect on musculoskeletal system (release of endorphins, activation of antinociceptive system, reduction of edema) anti-inflammatory effect (regulation of cytokine release, reduction of superoxide radicals, modulation of prostaglandin), regulation of local oxygenation and circulation, tissue repair (neutralization of preteolytic enzymes, fibroblast proliferation) and has an antimicrobial effect. Although it is also used in the treatment of plantar fasciitis, there are limited articles on this subject in the literature.
In our study, it was aimed to compare the effectiveness of ESWT and ozone injection therapy, which are two treatment strategies with regenerative action mechanisms, in patients with resistant plantar fasciitis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Berke Aras, Ass. Professor
- Phone Number: +905365851518
- Email: drberkearas@gmail.com
Study Locations
-
-
-
Ankara, Turkey, 06100
- Recruiting
- Ankara Bilkent City Hospital
-
Contact:
- Berke Aras, Associate Professor
- Phone Number: +905365851518
- Email: drberkearas@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be over 18 years old
- Heel pain lasting longer than 3 months
- Localized pain and tenderness on palpation on the medial aspect of the calcaneal tuberosity when the ankle is fully dorsiflexed.
- In the first step of walking, >50 mm according to VAS. and description of pain
- Presence of plantar fasciitis typical findings on ultrasonography (thickening more than 4 mm in the proximal plantar fascia with changes in fibril pattern)
- Failure to respond to conservative treatment before (nonsteroidal anti-inflammatory drugs, stretching, heel cushion, shoe modifications, orthotics, cold, heat, taping, massage)
Exclusion Criteria:
- being under the age of 18
- Any skin lesions in the heel area
- Inflammatory, rheumatic arthritis
- Having a history of fracture, trauma or operation in the heel area
- Systemic infection or malignancy
- Having a pacemaker
- Local injection to the heel area in the last 6 months or use of topical or oral nonsteroidal anti-inflammatory drugs in the last 2 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Ultrasound guided ozone injection therapy
|
Ultrasound guided ozone therapy
|
|
Active Comparator: Extracorporeal shock wave therapy
|
Extracorporeal shock wave therapy device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analog Scale
Time Frame: pre-treatment, immediately post-treatment and three months follow-up
|
measurement for pain severity, It is a value between 0-100.
"0" means no pain and "100" means maximum pain.
|
pre-treatment, immediately post-treatment and three months follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
plantar fascia thickness
Time Frame: pre-treatment, immediately post-treatment and three months follow-up
|
sonographic measurement for plantar fascia
|
pre-treatment, immediately post-treatment and three months follow-up
|
|
Foot Function İndex
Time Frame: pre-treatment, immediately post-treatment and three months follow-up
|
measurements for foot function.
An increase in the value indicates worse foot functions.
|
pre-treatment, immediately post-treatment and three months follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- E2-23-3838
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plantar Fascitis
-
NCT07576192Recruiting
-
NCT07628218RecruitingPlantar Fascitis | Plantar Fasciitis of Both Feet
-
NCT07471035Not yet recruitingPlantar Fascitis | Fasciitis | Chronic Plantar Fasciitis
-
NCT06706531Recruiting
-
NCT06394336Not yet recruiting
-
NCT05589285Recruiting
-
NCT03246087CompletedPlantar Fascitis
-
NCT05071365Completed
Clinical Trials on Ozone Generator
-
NCT05291715CompletedPain, Postoperative | Gingival Recession | Patient Satisfaction | Donor Site | Open Wound of Palate Without Complication | Free Gingival Grafts | Mucogingival Defects
-
NCT02733978Completed
-
NCT01192477Completed
-
NCT05544539CompletedImpacted Third Molar Tooth
-
NCT04789135Active, not recruitingBladder Pain Syndrome | Interstitial Cystitis, Chronic
-
NCT07325851Not yet recruitingChronic Pain | Chemotherapy-Induced Peripheral Neuropathy | Radiation Toxicity | Delayed Wound Healing | Refractory Symptoms
-
NCT05977309CompletedDiabetic Foot Ulcer | Wound Heal | Ozone